摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

N,N-dibenzyltetrahydro-2H-pyran-4-amine | 675112-44-4

中文名称
——
中文别名
——
英文名称
N,N-dibenzyltetrahydro-2H-pyran-4-amine
英文别名
N,N-dibenzyloxan-4-amine
N,N-dibenzyltetrahydro-2H-pyran-4-amine化学式
CAS
675112-44-4
化学式
C19H23NO
mdl
——
分子量
281.398
InChiKey
VJOWTHBNQUIMNV-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    398.4±37.0 °C(Predicted)
  • 密度:
    1.08±0.1 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    3.7
  • 重原子数:
    21
  • 可旋转键数:
    5
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.37
  • 拓扑面积:
    12.5
  • 氢给体数:
    0
  • 氢受体数:
    2

反应信息

  • 作为反应物:
    描述:
    N,N-dibenzyltetrahydro-2H-pyran-4-amine 在 palladium 10% on activated carbon 氢气 作用下, 以 乙醇 为溶剂, 20.0 ℃ 、689.49 kPa 条件下, 反应 72.0h, 生成 4-氨基四氢吡喃盐酸盐
    参考文献:
    名称:
    Pyrazolo[3,4-b]pyridine compounds, and their use as a PDE4 inhibitors
    摘要:
    该发明提供了化合物的结构式(I)或其盐:其中R2为H、C1-3烷基、正丁基、C1-2氟烷基、环丙基、环丁基、(环丙基)甲基、—CN或—CH2OH;R3为可选择地取代的C4-7环烷基或可选择地取代的杂环基(aa)、(bb)或(cc);R为H、甲基或乙基;R为H或甲基;R为H、甲基、乙基、正丙基、—C(O)-甲基或—C(O)—C1氟烷基;以及R为:—C(O)—(CH2)n—Ar、—C(O)-Het、—C(O)—C1-6烷基、—C(O)—C1氟烷基、—C(O)—(CH2)2—C(O)—NR15bNR15b、—C(O)—CH2—C(O)—NR15bNR15b、—C(O)—NR15b—(CH2)m1—Ar、—C(O)—NR15b—Het、—C(O)—NR15b—C1-6烷基、—C(O)—NR5aR5b、—S(O)2—(CH2)m2—Ar、—S(O)2-Het、—S(O)2—C1-6烷基或—CH2—Ar;或R和R5一起为—(CH2)p1—、—(CH2)2—X5—(CH2)2—、—C(O)—(CH2)p2—、—C(O)—N(R15)—(CH2)p3—;或NR4R5为子式(y)、(y1)、(y2)或(y3)。该发明提供了这些化合物作为磷酸二酯酶IV型(PDE4)的抑制剂以及用于治疗和/或预防炎症和/或过敏性疾病,如慢性阻塞性肺病(COPD)等的用途。
    公开号:
    US20090131431A1
  • 作为产物:
    参考文献:
    名称:
    Pyrazolo[3,4-b]pyridine compounds, and their use as a PDE4 inhibitors
    摘要:
    该发明提供了化合物的结构式(I)或其盐:其中R2为H、C1-3烷基、正丁基、C1-2氟烷基、环丙基、环丁基、(环丙基)甲基、—CN或—CH2OH;R3为可选择地取代的C4-7环烷基或可选择地取代的杂环基(aa)、(bb)或(cc);R为H、甲基或乙基;R为H或甲基;R为H、甲基、乙基、正丙基、—C(O)-甲基或—C(O)—C1氟烷基;以及R为:—C(O)—(CH2)n—Ar、—C(O)-Het、—C(O)—C1-6烷基、—C(O)—C1氟烷基、—C(O)—(CH2)2—C(O)—NR15bNR15b、—C(O)—CH2—C(O)—NR15bNR15b、—C(O)—NR15b—(CH2)m1—Ar、—C(O)—NR15b—Het、—C(O)—NR15b—C1-6烷基、—C(O)—NR5aR5b、—S(O)2—(CH2)m2—Ar、—S(O)2-Het、—S(O)2—C1-6烷基或—CH2—Ar;或R和R5一起为—(CH2)p1—、—(CH2)2—X5—(CH2)2—、—C(O)—(CH2)p2—、—C(O)—N(R15)—(CH2)p3—;或NR4R5为子式(y)、(y1)、(y2)或(y3)。该发明提供了这些化合物作为磷酸二酯酶IV型(PDE4)的抑制剂以及用于治疗和/或预防炎症和/或过敏性疾病,如慢性阻塞性肺病(COPD)等的用途。
    公开号:
    US20090131431A1
点击查看最新优质反应信息

文献信息

  • Pyrazolo[3,4-b] pyridine compounds, and their use as phosphodiesterase inhibitors
    申请人:Allen George David
    公开号:US20060089375A1
    公开(公告)日:2006-04-27
    The invention relates to a compound of formula (I) or a salt thereof: wherein: R 1 is C 1-4 alkyl, C 1-3 fluoroalkyl, —CH 2 CH 2 OH or —CH 2 CH 2 CO 2 C 1-2 alkyl; R 2 is a hydrogen atom (H), methyl or C 1 fluoroalkyl; R 3 is optionally substituted C 3-8 cycloalkyl or optionally substituted mono-unsaturated-C 5-7 cycloalkenyl or an optionally substituted heterocyclic group of sub-formula (aa), (bb) or (cc); in which n 1 and n 2 independently are 1 or 2; and in which Y is O, S, SO 2 , or NR 10 ; or R 3 is a bicyclic group (dd) or (ee): and wherein X is NR 4 R 5 or OR 5a . The compounds are phosphodiesterase (PDE) inhibitors, in particular PDE4 inhibitors. Also provided is the use of a compound of formula (I), or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment and/or prophylaxis of an inflammatory and/or allergic disease in a mammal such as a human, for example chronic obstructive pulmonary disease (COPD), asthma, or allergic rhinitis.
    本发明涉及一种化合物或其盐,其化学式为(I):其中:R1为C1-4烷基,C1-3氟烷基,-CH2CH2OH或-CH2CH2CO2C1-2烷基;R2为氢原子(H),甲基或C1氟烷基;R3为可选取代的C3-8环烷基或可选取代的单不饱和C5-7环烯基或亚式(aa),(bb)或(cc)的可选取代的杂环基;其中n1和n2独立地为1或2;且其中Y为O,S,SO2或NR10;或者R3为双环基(dd)或(ee):其中X为NR4R5或OR5a。该化合物为磷酸二酯酶(PDE)抑制剂,特别是PDE4抑制剂。本发明还提供了使用化合物(I)或其药学上可接受的盐制造药物,用于治疗和/或预防哺乳动物(例如人类)的炎症和/或过敏性疾病,例如慢性阻塞性肺疾病(COPD),哮喘或过敏性鼻炎。
  • Pyrazolo [3,4-b] pyridine compounds, and their use as phosphodiesterase inhibitors
    申请人:Allen George David
    公开号:US20060252790A1
    公开(公告)日:2006-11-09
    The invention relates to a compound of formula (I) or a salt thereof: wherein: R 1 is C 1-4 alkyl, C 1-3 fluoroalkyl or —(CH 2 ) 2 OH; R 2 is a hydrogen atom (H), methyl or C 1 fluoroalkyl; R 3a is a hydrogen atom (H) or C 1-3 alkyl; R 3 is optionally substituted branched C 3-6 alkyl, optionally substituted C 3-8 cycloalkyl, optionally substituted mono-unsaturated-C 5-7 cycloalkenyl, optionally substituted phenyl, or an optionally substituted heterocyclic group of sub-formula (aa), (bb) or (cc): in which n 1 and n 2 independently are 1 or 2; and Y is O, S, SO 2 , or NR 4 ; and wherein Het is of sub-formula (i), (ii), (iii), (iv) or (v): The compounds are phosphodiesterase (PDE) inhibitors, in particular PDE4 inhibitors. Also provided is the use of a compound of formula (I), or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment and/or prophylaxis of an inflammatory and/or allergic disease in a mammal such as a human, for example chronic obstructive pulmonary disease (COPD), asthma, or allergic rhinitis.
    本发明涉及式(I)化合物或其盐: 其中:R1是C1-4烷基,C1-3氟代烷基或—(CH2)2OH;R2是氢原子(H),甲基或C1氟代烷基;R3a是氢原子(H)或C1-3烷基;R3是可选的取代的支链C3-6烷基,可选的取代的C3-8环烷基,可选的取代的单不饱和C5-7环烯基,可选的取代的苯基,或者是亚式(aa),(bb)或(cc)的可选取代的杂环基: 其中n1和n2独立地为1或2;Y是O,S,SO2或NR4;而Het是亚式(i),(ii),(iii),(iv)或(v): 这些化合物是磷酸二酯酶(PDE)抑制剂,特别是PDE4抑制剂。还提供了使用式(I)化合物或其药学上可接受的盐制造药物,用于治疗和/或预防哺乳动物(例如人类)的炎症和/或过敏性疾病,例如慢性阻塞性肺疾病(COPD),哮喘或过敏性鼻炎。
  • Pyrazolo [3,4-B] pyridine Compounds and Their Use as Phosphodiesterase Inhibitors
    申请人:Allen George David
    公开号:US20070111995A1
    公开(公告)日:2007-05-17
    The invention provides pyrazolo[3,4-b]pyridine compounds of formula (I) having a —C(O)—NH—C(R 4 )(R 5 )-aryl substituent at the 5-position of the pyrazolo[3,4-b]pyridine ring system wherein at least one of R 4 and R 5 is not a hydrogen atom (H) compound or a salt thereof: wherein Ar has the sub-formula (x) or (z). These compounds are useful as inhibitors of PDE4.
    本发明提供了式(I)的吡唑并[3,4-b]吡啶化合物,其在吡唑并[3,4-b]吡啶环系的5位具有—C(O)—NH—C(R4)(R5)-芳基取代基,其中R4和R5中至少有一个不是氢原子(H)化合物或其盐:其中Ar具有亚式(x)或(z)。这些化合物可用作PDE4的抑制剂。
  • Pyrazolo[3,4-B]Pyridine Compound, and Its Use as a Pde4 Inhibitor
    申请人:Christensen Siegfried Benjamin
    公开号:US20080255186A1
    公开(公告)日:2008-10-16
    The invention provides N-[1,6-diethyl-4-(tetrahydro-2H-pyran-4-ylamino)-1H-pyrazolo[3,4-b]pyridin-5-yl]methyl}-3-methyl-5-isoxazolecarboxamide or a salt thereof, such as the compound or a pharmaceutically acceptable salt thereof. The invention also provides the use of the compound or salt as an inhibitor of phosphodiesterase type IV (PDE4.
    该发明提供了N-[1,6-二乙基-4-(四氢-2H-吡喃-4-基氨基)-1H-吡唑并[3,4-b]吡啶-5-基]甲基}-3-甲基-5-异噁唑羧酰胺或其盐,例如该化合物或其医药上可接受的盐。该发明还提供了该化合物或盐作为磷酸二酯酶IV型(PDE4)抑制剂的用途。
  • PYRAZOLO [3,4-B] PYRIDINE COMPOUNDS, AND THEIR USE AS PDE4 INHIBITORS
    申请人:Allen David George
    公开号:US20080132536A1
    公开(公告)日:2008-06-05
    The invention provides a compound of formula (I) or a salt thereof: wherein Ar has the sub-formula (x) or (z): and wherein R 3 is optionally substituted C 3-8 cycloalkyl, optionally substituted C 5-7 cycloalkenyl, an optionally substituted heterocyclic group (aa), (bb) or (cc), or a bicyclic group (ee); and wherein R 4 is H, C 1-3 alkyl, C 1-2 fluoroalkyl, cyclopropyl, —CH 2 OR 4a , —CH(Me)OR 4a , or —CH 2 CH 2 OR 4a ; and R 5 is inter alia H, C 1-8 alkyl, C 1-3 fluoroalkyl, C 3-8 cycloalkyl, certain substituted alkyl groups, —(CH 2 ) n 13 -Het, or optionally substituted phenyl or —CH 2 -Ph; or R 4 and R 5 taken together are —(CH 2 ) p 1 — or —(CH 2 ) p 3 —X 5 —(CH 2 ) p 4 —; provided that at least one of R 4 and R 5 is not a hydrogen atom (H). The invention also provides the use of the compounds as inhibitors of phosphodiesterase type IV (PDE4) and/or for the treatment and/or prophylaxis of inflammatory and/or allergic diseases such as chronic obstructive pulmonary disease (COPD), asthma, rheumatoid arthritis, allergic rhinitis or atopic dermatitis.
    该发明提供了式(I)的化合物或其盐: 其中Ar具有亚式(x)或(z): 其中,R3是可选的取代C3-8环烷基,可选的取代C5-7环烯基,可选的取代的杂环基(aa),(bb)或(cc),或者是双环基(ee); 其中,R4是氢,C1-3烷基,C1-2氟代烷基,环丙基,—CH2OR4a,—CH(Me)OR4a或—CH2CH2OR4a; 而R5则是包括氢、C1-8烷基、C1-3氟代烷基、C3-8环烷基、某些取代烷基、—(CH2)n13-Het,或可选取代的苯基或—CH2-Ph等的基团; 或者,R4和R5在一起是—(CH2)p1—或—(CH2)p3—X5—(CH2)p4—; 但是至少其中一个R4和R5不是氢原子(H)。 该发明还提供了将这些化合物用作磷酸二酯酶IV(PDE4)的抑制剂和/或用于治疗和/或预防炎症和/或过敏性疾病,如慢性阻塞性肺疾病(COPD)、哮喘、类风湿性关节炎、过敏性鼻炎或特应性皮炎的用途。
查看更多

同类化合物

(βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-盐酸沙丁胺醇 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-2-[((二苯基膦基)甲基]吡咯烷 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S)-(-)-2-{[[[[3,5-双(氟代甲基)苯基]氨基]硫代甲基]氨基}-N-(二苯基甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[[((1R,2R)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2-硝基苯基)磷酸三酰胺 (2,6-二氯苯基)乙酰氯 (2,3-二甲氧基-5-甲基苯基)硼酸 (1S,2S,3S,5S)-5-叠氮基-3-(苯基甲氧基)-2-[(苯基甲氧基)甲基]环戊醇 (1-(4-氟苯基)环丙基)甲胺盐酸盐 (1-(3-溴苯基)环丁基)甲胺盐酸盐 (1-(2-氯苯基)环丁基)甲胺盐酸盐 (1-(2-氟苯基)环丙基)甲胺盐酸盐 (-)-去甲基西布曲明 龙胆酸钠 龙胆酸叔丁酯 龙胆酸 龙胆紫 龙胆紫 齐达帕胺 齐诺康唑 齐洛呋胺 齐墩果-12-烯[2,3-c][1,2,5]恶二唑-28-酸苯甲酯 齐培丙醇 齐咪苯 齐仑太尔 黑染料 黄酮,5-氨基-6-羟基-(5CI) 黄酮,6-氨基-3-羟基-(6CI) 黄蜡,合成物 黄草灵钾盐